Literature DB >> 35068222

Identification of a 7-miRNA signature for predicting the prognosis of patients with lung adenocarcinoma.

Ruijun Liu1, Zhiyi Guo1, Jia Huang1, Jiantao Li1, Qiang Tan1, Qingquan Luo1.   

Abstract

The role of microRNAs (miRNAs) in tumor diagnosis and patients' prognosis has recently gained extensive research attention. This study was designed to analyze miRNA in lung adenocarcinoma (LUAD) using bioinformatics analysis and to identify novel biomarkers to predict overall survival (OS) for LUAD patients. Differential miRNA expression analysis was performed on LUAD, and normal tissues were extracted from The Cancer Genome Atlas (TCGA). Univariate Cox risk regression and least absolute shrinkage and selection operator (LASSO) Cox analysis were used to screen prognostic miRNAs and develop a risk score model. The prognostic performance of the system was examined utilizing the Kaplan-Meier and receiver operating characteristic (ROC) curves. Independent prognostic factors of LUAD were determined by multivariate Cox regression analysis. Nomogram was constructed according to the independent prognostic factors to evaluate the patients' one-, three- and five-year OS. A 7-miRNA signature based on miR-584-5p, miR-31-3p, miR-490-3, miR-4661-5p, miR-30e-5p, miR-582-5p, and miR-148a-3p was established. To categorize patients into high- and low-risk groups, the risk score was computed. The OS of the low-risk group was significantly longer than the high-risk group, and the signature showed high sensitivity and specificity in anticipating the one-, three- and five-year OS. The system was an independent factor in predicting the OS of LUAD patients and performed better when combined with the N stage in nomogram. A 7-miRNA signature developed in this study could accurately predict LUAD survival.

Entities:  

Keywords:  MiRNA; lung adenocarcinoma; prognosis; risk score

Mesh:

Substances:

Year:  2022        PMID: 35068222      PMCID: PMC9039494          DOI: 10.1177/15353702211067450

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  34 in total

1.  miR-582-5p is a potential prognostic marker in human non-small cell lung cancer and functions as a tumor suppressor by targeting MAP3K2.

Authors:  L-L Wang; M Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-11       Impact factor: 3.507

2.  microRNA-148a-3p inhibited the proliferation and epithelial-mesenchymal transition progression of non-small-cell lung cancer via modulating Ras/MAPK/Erk signaling.

Authors:  Qiong Xie; Zipu Yu; Yuan Lu; Jingya Fan; Yiming Ni; Liang Ma
Journal:  J Cell Physiol       Date:  2018-12-10       Impact factor: 6.384

3.  Integrative Proteomic Characterization of Human Lung Adenocarcinoma.

Authors:  Jun-Yu Xu; Chunchao Zhang; Xiang Wang; Linhui Zhai; Yiming Ma; Yousheng Mao; Kun Qian; Changqing Sun; Zhiwei Liu; Shangwen Jiang; Minghui Wang; Lin Feng; Lei Zhao; Ping Liu; Bo Wang; Xin Zhao; Hui Xie; Xiaoyun Yang; Liyuan Zhao; Yafei Chang; Jingya Jia; Xijun Wang; Yimin Zhang; Yaru Wang; Yikun Yang; Zhixiang Wu; Longhai Yang; Bin Liu; Teng Zhao; Shengguo Ren; Aihua Sun; Yang Zhao; Wantao Ying; Fei Wang; Guangshun Wang; Yi Zhang; Shujun Cheng; Jun Qin; Xiaohong Qian; Yi Wang; Jing Li; Fuchu He; Ting Xiao; Minjia Tan
Journal:  Cell       Date:  2020-07-09       Impact factor: 41.582

4.  TNM in non-small cell lung cancer: a staging system for all oncologists or just for surgeons?

Authors:  David Ball
Journal:  Ann Transl Med       Date:  2019-07

5.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

Review 6.  Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis.

Authors:  Manuela Ferracin; Massimo Negrini
Journal:  Expert Rev Mol Diagn       Date:  2015-09-04       Impact factor: 5.225

Review 7.  Tumor immunosurveillance in human cancers.

Authors:  Bernhard Mlecnik; Gabriela Bindea; Franck Pagès; Jérôme Galon
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

Review 8.  Development of miRNA-based therapeutic approaches for cancer patients.

Authors:  Ryou-U Takahashi; Marta Prieto-Vila; Isaku Kohama; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2019-02-26       Impact factor: 6.716

9.  Prognostic Value of Survival of MicroRNAs Signatures in Non-small Cell Lung Cancer.

Authors:  Bo Chen; Tianshun Gao; Weiwei Yuan; Weihong Zhao; Tza-Huei Wang; Jianqing Wu
Journal:  J Cancer       Date:  2019-10-06       Impact factor: 4.207

10.  An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma.

Authors:  Xuelian Li; Yunrui Shi; Zhihua Yin; Xiaoxia Xue; Baosen Zhou
Journal:  J Transl Med       Date:  2014-06-04       Impact factor: 5.531

View more
  1 in total

1.  Application of CT Imaging in Differential Diagnosis and Nursing of Endocrine Tumors.

Authors:  Xue Jiang; Weiwei Xu; Ying Zhao
Journal:  Contrast Media Mol Imaging       Date:  2022-08-08       Impact factor: 3.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.